Market Overview
The S&P/ASX 200 Index (ASX: XJO) is experiencing a challenging start to the week. In afternoon trade, the benchmark index has dropped by 0.45%, reaching 8,921.3 points. Despite this overall downturn, several ASX shares are performing well and defying the market trend. Below are four companies that are currently rising in value.
Monash IVF Group Ltd (ASX: MVF)
Monash IVF Group Ltd’s share price has surged by 14% to 75.7 cents. This rise comes after the fertility treatment company received a new non-binding takeover proposal from a consortium that includes Washington H. Soul Pattinson and Co Ltd (ASX: SOL). The previous offer was 80 cents per share, but this has now been increased to 90 cents per share. The consortium states that this amount represents the highest they are willing to offer unless a competing proposal emerges for all or a significant part of Monash IVF. The company’s board is currently evaluating the proposal, with input from its financial and legal advisers.
Pro Medicus Ltd (ASX: PME)
Pro Medicus Ltd’s share price has risen by 5% to $133.14. The health imaging technology company recently announced a five-year contract renewal with Northwestern Medicine. The contract, valued at $37 million, includes increased minimums and higher fees per transaction. Pro Medicus’ CEO, Dr Hupert, expressed satisfaction with the deal, noting that it reflects the growth in exam volumes since the company standardized on their platform five years ago.
Telix Pharmaceuticals Ltd (ASX: TLX)
Telix Pharmaceuticals Ltd’s share price has climbed by 8% to $15.87. Investors are showing interest in the radiopharmaceuticals company following a major collaboration with US-based Regeneron Pharmaceuticals (NASDAQ: REGN). The partnership could potentially yield up to US$2.1 billion in development and commercial milestone payments, along with low double-digit royalties if Telix chooses not to co-fund any program. Telix’s managing director and CEO, Christian Behrenbruch, highlighted the complementary capabilities of both companies and the potential for innovative biologics-based radiopharmaceuticals.
Woodside Energy Group Ltd (ASX: WDS)
Woodside Energy Group Ltd’s share price has increased by nearly 3% to $34.19. The energy giant’s shares are rising today due to a surge in oil prices above US$100 a barrel. This increase was driven by news that US President Donald Trump is threatening to blockade Iranian ports following the failure of initial peace talks between the two countries.
Additional Information
For investors considering purchasing Monash IVF Group shares, it is essential to evaluate various factors. Motley Fool investing expert Scott Phillips has identified what he believes are the 5 best stocks for investors to buy right now, although Monash IVF Group was not among them. The online investing service Motley Fool Share Advisor has provided thousands of members with stock picks that have significantly outperformed the market.
More reading includes insights into how ASX 200 energy stocks like Woodside and Santos are surging in a sinking market, analysis of AGL, Origin Energy, and Woodside shares, and updates on Telix’s share price movement following a $3 billion US news announcement. Additionally, there is information on the 10 most shorted ASX shares and reasons behind Pro Medicus shares outperforming the market.
Motley Fool contributor James Mickleboro has positions in Pro Medicus and Woodside Energy Group Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Regeneron Pharmaceuticals, Telix Pharmaceuticals, and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia’s parent company has also recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia has recommended Pro Medicus and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article provides general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
